rhngf for neurotrophic keratitis first line
|
|
- Nigel Fox
- 5 years ago
- Views:
Transcription
1 September 2015 Horizon Scanning Research & Intelligence Centre rhngf for neurotrophic keratitis first line LAY SUMMARY This briefing is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes or commissioning without additional information. Neurotrophic keratitis is a condition in which the cornea, the front part of the eye, becomes damaged. It is caused by nerve damage which leads to ulcers forming on the cornea that are very difficult to treat. rhngf is a new drug for the treatment of neurotrophic keratitis that is given as eye drops. Some studies have suggested the rhngf may be helpful for people who already have quite severe damage to their eye. If rhngf is licensed for use in the UK, it could be a new treatment option for patients with this condition, which would reduce the need for surgery. NIHR HSRIC ID: This briefing presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health. NIHR Horizon Scanning Research & Intelligence Centre, University of Birmingham. nihrhsc@contacts.bham.ac.uk Web:
2 TARGET GROUP Neurotrophic keratitis (NK): due to any underlying aetiology; stage 2 or 3 first line. TECHNOLOGY DESCRIPTION rhngf (Sentinel) is a recombinant human nerve growth factor that targets two receptors, p75ntf and TrkA. Nerve growth factor (NGF) is essential for the survival and growth of sympathetic and sensory neurons, as well as the differentiation of neurons in the central nervous system. The biological effects of NGF are mediated by activation of NGF receptors that are expressed on the anterior segment of the eye (iris, ciliary body, lens, cornea and conjunctiva), intra-ocular tissues, the central visual pathway (lateral geniculate nucleus and visual cortex), as well as the optic nerve and retina. In the phase I/II clinical trial, rhngf is administered as either a 10µg/ml or 20µg/ml eye drop solution, at one drop six times daily. rhngf does not currently have Marketing Authorisation in the EU for any indication. rhngf is also currently in phase II development for the treatment of xerophthalmia. INNOVATION and/or ADVANTAGES If licensed, rhngf will offer an additional treatment option for patients with NK who currently have few effective therapies available. DEVELOPER Dompé. AVAILABILITY, LAUNCH OR MARKETING rhngf is a designated orphan drug in the USA. In phase II clinical trials. PATIENT GROUP BACKGROUND NK is a degenerative disease of the corneal epithelium resulting from impaired corneal innervation 1. This results in a decrease in or absence of corneal sensation and ultimately leads to epithelial keratopathy, ulceration and perforation 2. The most common causes of impairment of corneal sensation are viral infection (herpes simplex and herpes zoster keratoconjunctivitis), intracranial space-occupying lesions (neuroma, meningioma and aneurysms), and/or neurosurgical procedures that damage the trigeminal ophthalmic branch 3,4. Other ocular causes include ocular surface injury (chemical or thermal burns), corneal dystrophy and contact lens wear 3. Many systemic conditions are also associated with the development of corneal anaesthesia, including diabetes mellitus, multiple sclerosis and congenital syndromes 3,4. 2
3 NK is classified into three stages according to severity 1,3 : Stage 1 mild, non-specific signs and symptoms, characterised by corneal epithelial changes with dry and cloudy cornea. Stage 2 non-healing corneal epithelial defect, characterised by recurrent and/or persistent epithelial defects which are surrounded by poorly adherent opaque and oedematous epithelium. Stage 3 often ensues if stage 1 and 2 are not appropriately treated. Characterised by corneal ulcer with stromal involvement which may be complicated by stromal melting and progression to corneal perforation. NHS or GOVERNMENT PRIORITY AREA NHS England. 2013/14 NHS Standard Contract for Specialised Ophthalmology (Adult). D12/S/a. NHS England. 2013/14 NHS Standard Contract for Ophthalmic Pathology Service (All Ages). D12/S(HSS)/b. CLINICAL NEED and BURDEN OF DISEASE NK is classified as an orphan disease with an estimated prevalence of less than 5 per 10,000 individuals worldwide 3. Although the epidemiology of NK is uncertain, the prevalence and incidence of the disease may be estimated from the epidemiological data on conditions associated with NK 3. NK develops in an average 6% of herpetic keratitis cases, which have a prevalence of 149 per 100,000 population, and in 12.8% of herpes zoster keratitis cases, which have a prevalence of 26 per 100,000 population. In addition, 2.8% of patients who underwent surgical procedures for trigeminal neuralgia (1.5 per 10,000 population 5 ) subsequently developed NK 3. The percentage of NK cases associated with other conditions, such as diabetes mellitus, multiple sclerosis, corneal dystrophy, and congenital diseases is not known. In , there were 2,487 hospital admissions for keratitis (ICD-10 H16) equating to 10,639 bed days and 2,642 finished consultant episodes in England 6. The population likely to be eligible to receive rhngf could not be estimated from available published sources. PATIENT PATHWAY RELEVANT GUIDANCE NICE Guidance NICE interventional procedure guidance. Photochemical corneal collagen cross-linkage using riboflavin and ultraviolet A for keratoconus and keratectasia (IPG466). September NICE interventional procedure guidance. Phototherapeutic laser keratectomy for corneal surface irregularities (IPG358). September NICE interventional procedure guidance. Corneal endothelial transplantation (IPG304). June NICE interventional procedure guidance. Corneal implants for keratoconus (IPG227). July
4 NICE interventional procedure guidance. Tissue-cultured limbal stem cell allograft transplant for regrowth of corneal epithelium (IPG216). April NICE interventional procedure guidance. Insertion of hydrogel keratoprosthesis (IPG69). June CURRENT TREATMENT OPTIONS Current treatment of NK aims to prevent progression of corneal damage and to promote epithelial healing 2. Therapy should be promptly initiated, and is based on the clinical stage of the disease 1,2 : Stage 1 o Preservative-free artificial tears. o Punctual occlusion. Stage 2 o Prophylactic antibiotic drops and preservative-free artificial tears. o Corneal or scleral therapeutic contact lenses. o Lateral tarsorrhaphy (surgical closure of the eyelids). o Amniotic membrane transplantation over the epithelial defect. o Injection of botulinum A toxin into the upper eyelid levator muscle. Stage 3 o Prophylactic antibiotic drops and preservative-free artificial tears. o In cases of stromal melting, topical collagenase inhibitors such as N-acetylcysteine, tetracycline or medroxyprogesterone, may be administered. o Lateral tarsorrhaphy. o Conjunctival flap surgery. o Lamellar or penetrating keratoplasty. o Amniotic membrane transplantation. o Larger defects require lamellar or penetrating keratoplasty. EFFICACY and SAFETY Trial Sponsor Status Source of information Location Design Participants Schedule Follow-up Primary outcome/s Secondary outcome/s REPARO, NCT , NGF0212, ; rhngf vs placebo; phase I/II. Dompé farmaceutici SpA. Ongoing. Trial registry 7, manufacturer. EU (incl UK). Randomised, placebo-controlled. n=174; aged 18 years; stage 2 (persistent epithelial defect) or stage 3 (corneal ulcer) neurotrophic keratitis; refractory to one or more conventional non-surgical treatment(s); no prior surgical procedure(s) for the treatment of neurotrophic keratitis; no other ocular disease requiring topic ocular treatment. Randomised to rhngf administered as a 20µg/ml eye drop solution at one drop six times daily; or rhngf 10µg/ml eye drop solution at one drop six times daily; or placebo eye drop solution at one drop six times daily. Active treatment for 8 weeks, follow-up at 48 or 56 weeks. Complete healing of persistent epithelial defect or corneal ulcer. Presence of Anti-NGF antibodies, change in ocular tolerability. 4
5 Expected reporting date Primary completion date reported as Sept ESTIMATED COST and IMPACT COST The cost of rhngf is not yet known. IMPACT - SPECULATIVE Impact on Patients and Carers Reduced mortality/increased length of survival Other. Impact on Health and Social Care Services Increased use of existing services Re-organisation of existing services Other. Reduced symptoms or disability: the company reports rhngf has the potential to be the first potentially curative treatment for patients with stage 2 and 3 NK. No impact identified Decreased use of existing services: the company claim that treatment of NK with rhngf could cause a reduction in need for ophthalmic visits and repetitive surgical procedures for patients with this disease. Need for new services None identified Impact on Costs and Other Resource Use Increased drug treatment costs Other increase in costs. Other: uncertain unit cost compared to existing treatments. Expert opinion suggests that treatment with rhngf could result in reduction in the use of services, particularly the frequency and number of follow-up appointments, which will mitigate against the cost of the new drug (presently unknown) a. Reduced drug treatment costs Other reduction in costs. None identified Other Issues Clinical uncertainty or other research question identified. None identified a Expert personal communication. 5
6 REFERENCES 1 Wells JR and Michelson MA. Diagnosing and treating neurotrophic keratitis. EyeNet Magazine. July-August Bonini S, Rama P, Olzi D et al. Neurotrophic keratitis. Eye 2003;17: Sacchetti M and Lambiase A. Diagnosis and management of neurotrophic keratitis. Clinical Ophthalmology 2014;8: Ophthalmology Management. Neurotrophic Keratopathy: New Treatment Strategies. Accessed 20 August Bhatti MT and Patel R. Neuro-ophthalmic consideration in trigeminal neuralgia and its surgical treatment. Current Opinion in Ophthalmology 2005;16; Health & Social Care Information Centre. Hospital episode statistics for England. Inpatients statistics, ClinicalTrials.gov. Evaluation of efficacy of 20µg/ml rhngf in patients with stage 1 and 2 neurotrophic keratitis. Accessed 20 August
Botulinum toxin A (Dysport) for hyperhidrosis of the axillae
April 2016 Horizon Scanning Research & Intelligence Centre Botulinum toxin A (Dysport) for hyperhidrosis of the axillae LAY SUMMARY This briefing is based on information available at the time of research
More informationHorizon Scanning Centre November Spheroids of human autologous matrix-associated chondrocytes (Chondrosphere) for articular cartilage defects
Horizon Scanning Centre November 2014 Spheroids of human autologous matrix-associated chondrocytes (Chondrosphere) for articular cartilage defects SUMMARY NIHR HSC ID: 8515 This briefing is based on information
More informationInterventional procedures guidance Published: 25 September 2013 nice.org.uk/guidance/ipg466
Photochemical corneal collagen cross-linkage using riboflavin and ultraviolet A for keratoconus and keratectasia Interventional procedures guidance Published: 25 September 2013 nice.org.uk/guidance/ipg466
More informationPhotochemical corneal collagen cross-linkage using riboflavin and ultraviolet A for keratoconus and keratectasia
Photochemical corneal collagen cross-linkage using riboflavin and ultraviolet A for keratoconus and keratectasia Issued: September 2013 guidance.nice.org.uk/ipg466 NICE has accredited the process used
More informationSubject Index. Atopic keratoconjunctivitis (AKC) management 16 overview 15
Subject Index Acanthamoeba keratitis, see Infective keratitis Acute allergic conjunctivitis AKC, see Atopic keratoconjunctivitis Allergy acute allergic conjunctivitis 15 atopic keratoconjunctivitis 15
More informationHorizon Scanning Centre March Cholic acid (Orphacol) for inborn errors of primary bile acid synthesis first line SUMMARY NIHR HSC ID: 9468
Horizon Scanning Centre March 2014 Cholic acid (Orphacol) for inborn errors of primary bile acid synthesis first line SUMMARY NIHR HSC ID: 9468 This briefing is based on information available at the time
More informationMedical Affairs Policy
Medical Affairs Policy Service: Corneal Treatments and Specialized Contact Lenses (Corneal remodeling, Corneal transplant, Corneal collagen crosslinking, Intrastromal Rings- INTACS, Keratoconus treatments,
More informationHorizon Scanning Centre November Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688
Horizon Scanning Centre November 2012 Faldaprevir with BI 207127 for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688 This briefing is based on information available at the time of research
More informationCORNEAL CONDITIONS CORNEAL TRANSPLANTATION
GENERAL INFORMATION CORNEAL CONDITIONS CORNEAL TRANSPLANTATION WHAT ARE CORNEAL CONDITIONS? The cornea is the clear outer layer of the eye. Shaped like a dome, it helps to protect the eye from foreign
More informationOlesoxime for amyotrophic lateral sclerosis first line
Olesoxime for amyotrophic lateral sclerosis first line May 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationKTE-C19 for relapsed or refractory mantle cell lymphoma
NIHR Innovation Observatory Evidence Briefing: July 2017 KTE-C19 for relapsed or refractory mantle cell lymphoma NIHRIO (HSRIC) ID: 11846 NICE ID: 9122 LAY SUMMARY Mantle cell lymphoma is an uncommon type
More informationWhat are some common conditions that affect the cornea?
What are some common conditions that affect the cornea? Injuries After minor injuries or scratches, the cornea usually heals on its own. Deeper injuries can cause corneal scarring, resulting in a haze
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationDepartment of Ophthalmology
Department of Ophthalmology Period : 02/July/18 to 30/August/18 Semester : 7 th Semester Lecture Lesson Plan Sr. Date Topic Lesson plan Name of Faculty No. 1 02.07.18 Lens- Lens-Anatomy, Classification
More informationDr. D. Y. Patil Medical College, Pimpri, Pune
Dr. D. Y. Patil Medical College, Pimpri, Pune - 411 018 Period : 04/July/16 to 22/September/16 Semester : 7 th Semester Department : Ophthalmology Lecture Lesson Plan Sr No Date Topic Learning objectives
More informationCilengitide (Impetreve) for glioblastoma multiforme. February 2012
Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationDepartment of Ophthalmology
Period : 03/July/17 to 07/September/17 Semester : 7 th Semester Department of Ophthalmology Lecture Lesson Plan Sr 1 03.07.17 Uvea-Anatomy, Uvea-Anatomy, Classification of Uveitis Dr R Paranjpe Classification
More informationImplantation of a corneal graft keratoprosthesis for severe corneal opacity in wet blinking eyes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Implantation of a corneal graft keratoprosthesis for severe corneal opacity in wet blinking eyes The cornea
More informationGENERAL INFORMATION CORNEAL TRANSPLANTATION
GENERAL INFORMATION CORNEAL TRANSPLANTATION WHAT IS CORNEAL TRANSPLANTATION? A corneal transplant is an operation where a damaged or diseased cornea is replaced with donated, healthy tissue. Also called
More informationInsulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes
Insulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationLacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011
Lacosamide (Vimpat) for partial-onset epilepsy monotherapy This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationTicagrelor (Brilique) for peripheral arterial disease
July 2016 Horizon Scanning Research & Intelligence Centre Ticagrelor (Brilique) for peripheral arterial disease LAY SUMMARY This briefing is based on information available at the time of research and a
More informationHorizon Scanning Centre November Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line
Horizon Scanning Centre November 2012 Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line SUMMARY NIHR HSC ID: 5206 This briefing is based on information available
More informationCodes for Medically Necessary Contact Lenses
Codes for Medically Necessary Contact Lenses CPT Codes for Medically Necessary Prescribing Preamble for the 9231X Codes The prescription of contact lenses includes specification of optical and physical
More informationPATIENT INFORMATION ON CORNEAL GRAFT
PATIENT INFORMATION ON CORNEAL GRAFT (TRANSPLANT) SURGERY M ANANDAN What is the cornea? The clear window of the eye approximately 0.5mm thick and 12mm across. It lies in front of the fluid filled anterior
More informationLenti D for adrenoleukodystrophy in boys NIHRIO (HSRIC) ID: 7992 NICE ID: 8732
NIHR Innovation Observatory Evidence Briefing: May 2017 Lenti D for adrenoleukodystrophy in boys NIHRIO (HSRIC) ID: 7992 NICE ID: 8732 LAY SUMMARY Adrenoleukodystrophy (ALD), otherwise known as Lorenzo
More informationAR101 peanut allergy immunotherapy for adult and paediatric patients
AR101 peanut allergy immunotherapy for adult and paediatric patients NIHRIO (HSRIC) ID: 11815 NIHR Innovation Observatory Evidence Briefing: May 2017 NICE ID: 8773 LAY SUMMARY Food allergy occurs when
More informationClinical Commissioning Policy Proposition: Keratoprosthesis for corneal blindness
Clinical Commissioning Policy Proposition: Keratoprosthesis for corneal blindness Reference: NHS England 1618 First published: Month Year Prepared by NHS England Specialised Services Clinical Reference
More informationCornea & External Disease research at Moorfields
Recruiting Research Studies Cornea & External Disease research at Moorfields Moorfields Eye Hospital wants to improve access to clinical research studies for all patients within the NHS and provide the
More informationCabozantinib for medullary thyroid cancer. February 2012
Cabozantinib for medullary thyroid cancer February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationTHERAPEUTIC CONTACT LENSES
THERAPEUTIC CONTACT LENSES Prof. Univ. Dr. Adriana Stanila Victor Papilian Faculty of Medicine Emergency Academic Hospital Sibiu Ocular Surface Research Center ROMANIA INTRODUCTION therapeuein greac =
More informationSclerokeratoplasty David S. Chu, M.D. Cases
Sclerokeratoplasty David S. Chu, M.D. Cases Case 1 40 year-old female from Peru presented to our Service with inflamed OS for 2 months duration. Her symptoms began as red painful OS, which progressively
More informationGas Permeable Scleral Contact Lens. Description
Subject: Gas Permeable Scleral Contact Lens Page: 1 of 6 Last Review Status/Date: December 2013 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 3 Gas Permeable
More informationEverolimus (Votubia) for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis first line or post surgery
Everolimus (Votubia) for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis first line or post surgery April 2011 This technology summary is based on information
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress MANAGEMENT OF CORNEAL ULCERS IN SMALL ANIMALS Robin G Stanley, BVSc(Hons), FACVSc-Ophthalmology Animal Eye Care
More informationSome of the ophthalmic surgeries
Some of the ophthalmic surgeries Some of the ophthalmic surgeries performed at the DMV Center. This document presents some types of the surgeries performed by the ophthalmology service at the DMV veterinary
More informationNEW OPPORTUNITIES OF USING THERAPEUTICAL CONTACT LENSES IN OCULAR SURGERY
NEW OPPORTUNITIES OF USING THERAPEUTICAL CONTACT LENSES IN OCULAR SURGERY Authors: Prof univ. dr. Adriana Stănilă, Dr. Elena Mihai, Dr. Adrian Teodoru, Dr. IonuŃ Costache The Clinical Department of Op
More informationPasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line
Pasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line December 2010 This technology summary is based on information available at the time of research and a limited literature
More informationNeurotrophic Ulcer after Cataract Surgery: New Treatment
Cronicon OPEN ACCESS EC OPHTHALMOLOGY Case Report Neurotrophic Ulcer after Cataract Surgery: New Treatment Ronald Mauricio Sanchez-Avila 1,3 * and Jesus Merayo-Lloves 1,2,3 1 Institute University Fernandez-Vega,
More informationNovel therapies for the treatment of persistent corneal epithelial defects
Novel therapies for the treatment of persistent corneal epithelial defects Disclosures I have no financial interests in any of the techniques or products discussed. Bennie H. Jeng, M.D. Associate Professor
More informationSAGE-547 for super-refractory status epilepticus
NIHR Innovation Observatory Evidence Briefing: April 2017 SAGE-547 for super-refractory status epilepticus NIHRIO (HSRIC) ID: 10866 NICE ID: 8456 Status epilepticus is a single epileptic seizure lasting
More informationRiociguat for chronic thromboembolic pulmonary hypertension
Riociguat for chronic thromboembolic pulmonary hypertension This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationBelinostat (Beleodaq) with CHOP for treatment of patients with peripheral T cell lymphoma, 1st line
NIHR Innovation Observatory Evidence Briefing: September 2017 Belinostat (Beleodaq) with CHOP for treatment of patients with peripheral T cell lymphoma, 1st line NIHRIO (HSRIC) ID: 12674 NICE ID: 9532
More informationCertolizumab pegol (Cimzia) for chronic plaque psoriasis in adults
NIHR Innovation Observatory Evidence Briefing: April 2017 Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults NIHRIO (HSRIC) ID: 2406 NICE ID: 9112 LAY SUMMARY Plaque psoriasis is the most
More informationCabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel
Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel April 2009 This technology summary is based on information available at the time of research and a
More informationICD-10-CM Cornea. Type RT LT OU SINGLE CODE UNSPECIFIED. Acute atopic conjunctivitis H10.11 H10.12 H10.13 X H10.10
ICD-10-CM Cornea Conjunctiva Acute atopic conjunctivitis H10.11 H10.12 H10.13 H10.10 Acute chemical conjunctivitis H10.211 H10.212 H10.213 H10.219 Acute conjunctivitis, unspecified H10.31 H10.32 H10.33
More informationHorizon Scanning Centre November Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887
Horizon Scanning Centre November 2012 Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887 This briefing is based on information available at the time of research and a
More informationHistory. Examination. Diagnosis/Course
History A 51 year-old female with a history of chronic dry eyes and photosensitivity was referred for evaluation. She reported a five year history of symptoms of frequent irritation and photophobia in
More informationNational Horizon Scanning Centre. Decitabine (Dacogen) for myelodysplastic syndrome. April 2008
Decitabine (Dacogen) for myelodysplastic syndrome April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be
More informationHorizon Scanning Centre November 2012
Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based
More informationHerpes Zoster Ophtalmicus in a HIV positive patient: A Case Report
ISPUB.COM The Internet Journal of Neurology Volume 9 Number 2 Herpes Zoster Ophtalmicus in a HIV positive patient: A Case Report G Lopez Bejerano, Y Graza Fernandez Citation G Lopez Bejerano, Y Graza Fernandez..
More informationStrategies for Anterior Segment Disease Management Mile Brujic, OD, FAAO 1409 Kensington Blvd Bowling Green, OH
Strategies for Anterior Segment Disease Management Mile Brujic, OD, FAAO 1409 Kensington Blvd Bowling Green, OH 43402 brujic@prodigy.net 419-261-9161 Summary As optometry s scope of practice continues
More informationNEOD001 for amyloid light-chain (AL) amyloidosis
NIHR Innovation Observatory Evidence Briefing: October 2017 NEOD001 for amyloid light-chain (AL) amyloidosis NIHRIO (HSRIC) ID: 10617 NICE ID: 8803 LAY SUMMARY Amyloid light-chain (AL) amyloidosis is caused
More informationVoxelotor for sickle cell disease
NIHR Innovation Observatory Evidence Briefing: November 2017 Voxelotor for sickle cell disease NIHRIO (HSRIC) ID: 10748 NICE ID: 9700 LAY SUMMARY Sickle cell disease (SCD) describes a group of inherited
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationProgram Requirements for Fellowship Education in Cornea, External Diseases & Refractive Surgery*
Program Requirements for Fellowship Education in Cornea, External Diseases & Refractive Surgery* I. Introduction A. Definition and Scope of Subspecialty Fellowship training requires more in depth education
More informationHerpetic Eye Disease Jason Duncan, OD, FAAO Diplomate, American Board of Optometry Associate Professor, Southern College of Optometry
Herpetic Eye Disease Jason Duncan, OD, FAAO Diplomate, American Board of Optometry Associate Professor, Southern College of Optometry I have what?! How to break the news Meet the Herpes Quick virology
More informationDegenerations. Conditions with cloudy cornea at birth or in infancy
Dermoids The lesions are choristomas, which are congenital masses of tissue that have been dislocated from their normal position Limbal dermoids--overlapping the cornea and sclera, often inferotemporally
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationCorneal Ulceration. Client Information Sheet Copyright Bilton Veterinary Centre All rights Reserved. What is the cornea?
What is the cornea? Corneal Ulceration The cornea is the central clear part of the eye that is surrounded by the white of the eye called the Sclera. Looking through the cornea, you can see the coloured
More informationApplication of Umbilical Cord Serum Eyedrops for the Treatment of Neurotrophic Keratitis
Application of Umbilical Cord Serum Eyedrops for the Treatment of Neurotrophic Keratitis Kyung-Chul Yoon, MD, PhD, 1 In-Cheon You, MD, 1 Seong-Kyu Im, MD, 1 Tae-Sun Jeong, MD, 1 Yeoung-Geol Park, MD, PhD,
More informationDr. Harvey Richman, OD, FAAO, FCOVD Diplomate American Board of Optometry Executive Committee AOA Third Party Center Founder Ask the AOA Coding
Dr. Harvey Richman, OD, FAAO, FCOVD Diplomate American Board of Optometry Executive Committee AOA Third Party Center Founder Ask the AOA Coding Experts 92000 Codes Special Ophthalmological Services Describe
More informationRecurrent Corneal Erosion Syndrome
Eye Care Centre NHS Foundation Trust Recurrent Corneal Erosion Syndrome Information for patients Every Matters 1 What is recurrent corneal erosion syndrome? Recurrent corneal erosion syndrome is repeated
More informationHorizon Scanning Centre March Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798
Horizon Scanning Centre March 2015 Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798 This briefing is based on information available at the time of research and a limited
More informationUlcerative Keratitis (Type of Inflammation of the Cornea) Basics
Ulcerative Keratitis (Type of Inflammation of the Cornea) Basics OVERVIEW Keratitis is inflammation of the cornea; the cornea is the clear outer layer of the front of the eye The corneal epithelium is
More informationAxicabtagene ciloleucel IV for relapsed/refractory acute lymphoblastic leukaemia in children and adolecents (aged 2-21 years) second line
NIHR Innovation Observatory Evidence Briefing: August 2017 Axicabtagene ciloleucel IV for relapsed/refractory acute lymphoblastic leukaemia in children and adolecents (aged 2-21 years) second line NIHRIO
More informationFailure of amniotic membrane transplantation in the treatment of acute ocular burns
Br J Ophthalmol 2001;85:1065 1069 1065 ORIGINAL ARTICLES Clinical science Failure of amniotic membrane transplantation in the treatment of acute ocular burns Annie Joseph, Harminder S Dua, Anthony J King
More informationClinical Practice Guide for the Diagnosis, Treatment and Management of Anterior Eye Conditions. April 2018
Clinical Practice Guide for the Diagnosis, Treatment and Management of Anterior Eye Conditions This Clinical Practice Guide provides evidence-based information about current best practice in the management
More informationDifferential Diagnosis of Conjunctivitis and Keratoconjunctivitis
Differential Diagnosis of Conjunctivitis and Keratoconjunctivitis Dr. Victor Malinovsky 2006 Mechanical-Physical Trauma Corneal Abrasions Abrasions (interpalpebral/variable): a focal loss of epithelium
More informationNational Horizon Scanning Centre. Methylnaltrexone (MOA-728) for postoperative ileus. April 2008
(MOA-728) for postoperative ileus April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More informationAmniotic Membrane Transplantation In Ocular Surface Disorders
Orginal Article Amniotic Membrane Transplantation In Ocular Surface Disorders Khalid Iqbal Talpur, Faiz Muhammad Halepota, Muhammad Pak J Ophthalmol 2005, Vol. 22 No. 3.................................................................................................
More informationOcular Pathology. I. Congenital and/or developmental. A. Trisomy 21. Hypertelorism (widely spaced eyes) Keratoconus (cone shaped cornea)
I. Congenital and/or developmental Robbins Pathologic Basis of Disease, 6 th Ed. A. Trisomy 21 Hypertelorism (widely spaced eyes) Keratoconus (cone shaped cornea) Focal hypoplasia of iris Cataracts frequently
More informationAging & Ophthalmology
Aging & Ophthalmology Pr Jean-Marie Rakic Dr Denis Malaise January 2018 Major ocular diseases 1. Cataract 2. Age-related macular degeneration 3. Ischemic optic neuropathy 4. Horton arteritis 5. Glaucoma
More informationGENERAL INFORMATION MOSMAN CLINIC
GENERAL INFORMATION MOSMAN CLINIC visioneyeinstitute.com.au Quality Management. ISO 9001 SPECIALIST EYE CARE FOR PATIENTS Our clinic provides comprehensive, high-quality eye care to Mosman and surrounding
More informationEmapalumab for primary haemophagocytic lymphohistiocytosis
NIHR Innovation Observatory Evidence Briefing: February 2018 Emapalumab for primary haemophagocytic lymphohistiocytosis NIHRIO (HSRIC) ID: 8727 NICE ID: 8735 LAY SUMMARY Haemophagocytic lymphohistiocytosis
More informationSetmelanotide for pro-opiomelanocortin deficiency obesity
NIHR Innovation Observatory Evidence Briefing: September 2017 Setmelanotide for pro-opiomelanocortin deficiency obesity NIHRIO (HSRIC) ID: 8496 NICE ID: 9505 LAY SUMMARY Body fat and food intake are regulated
More informationNEW YORK UNIVERSITY SCHOOL OF MEDICINE DEPARTMENT OF OPHTHALMOLOGY EDUCATIONAL OBJECTIVES AND GOALS
NEW YORK UNIVERSITY SCHOOL OF MEDICINE DEPARTMENT OF OPHTHALMOLOGY EDUCATIONAL OBJECTIVES AND GOALS Revision Date: 6/30/06 Distribution Date: 7/6/06 The Department of Ophthalmology at the NYU Medical Center
More informationD90 (27/10/2005) Final SmPC NL/H/653/01
1/6 1. NAME OF THE MEDICINAL PRODUCT MONOFREE DEXAMETHASON 1 mg/ml, eye drops, solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml solution contains 1 mg of dexamethasone phosphate as dexamethasone
More informationDr Jo-Anne Pon. Dr Sean Every. 8:30-9:25 WS #70: Eye Essentials for GPs 9:35-10:30 WS #80: Eye Essentials for GPs (Repeated)
Dr Sean Every Ophthalmologist Southern Eye Specialists Christchurch Dr Jo-Anne Pon Ophthalmologist Southern Eye Specialists, Christchurch Hospital, Christchurch 8:30-9:25 WS #70: Eye Essentials for GPs
More informationNational Horizon Scanning Centre. Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis. April 2008
Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationVolixibat for non-alcoholic steatohepatitis (NASH)
NIHR Innovation Observatory Evidence Briefing: October 2017 Volixibat for non-alcoholic steatohepatitis (NASH) NIHRIO (HSRIC) ID: 10240 NICE ID: 9524 LAY SUMMARY Non-alcoholic steatohepatitis (NASH) is
More information2009 Eye Banking Statistical Report Eye Bank Association of America th Street, N.W. Suite 1010 Washington, DC Phone (202) Fax
2009 Eye Banking Statistical Report Eye Bank Association of America 1015 18th Street, N.W. Suite 1010 Washington, DC 20036 Phone (202) 775-4999 Fax (202) 429-6036 www.restoresight.org Introduction 2009
More informationDISTANCE LEARNING COURSE. Scope of the Eye Care Practice , BSM Consulting All rights reserved.
DISTANCE LEARNING COURSE Scope of the Eye Care Practice 2008 2012, BSM Consulting All rights reserved. Table of Contents OVERVIEW... 1 THREE O'S IN EYE CARE... 1 ROUTINE VS. MEDICAL EXAMS... 2 CONTACT
More informationCorneal transplant surgery. Brought to you in association with EIDO Healthcare and endorsed by the Royal College of Surgeons England.
Corneal transplant surgery Brought to you in association with EIDO Healthcare and endorsed by the Royal College of Surgeons England. Discovery has made every effort to ensure that we obtained the information
More informationThe cataract laser technology of tomorrow is here for you today. See inside to learn about all your exciting new options
The cataract laser technology of tomorrow is here for you today. See inside to learn about all your exciting new options What is a cataract? A cataract is a clouding of the lens of the eye. This blocks
More informationInnovation In Ophthalmology
Innovation In Ophthalmology INVELTYS TM Approval August 2018 Disclaimers and Notices This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationPRECISION PROGRAM. Injection Technique Quick-Reference Guide. Companion booklet for the Video Guide to Injection Technique
Injection Technique Quick-Reference Guide PRECISION PROGRAM Companion booklet for the Video Guide to Injection Technique Available at www.ozurdexprecisionprogram.com Provides step-by-step directions with
More informationPREAMBLE TO MSC PAYMENT SCHEDULE: OPTOMETRY SERVICES
PREAMBLE TO MSC PAYMENT SCHEDULE: OPTOMETRY SERVICES A. GENERAL PROVISIONS 1. Eye Examination Benefits Optometric benefits are services defined in Section 23 of the Medical and Health Care Services Regulations,
More informationQuestion Papers of BHU
Question Papers of BHU M.S. (April) Examination, 2009 Paper I: Anatomy, Embryology, Physiology of Eye and Adnexa 1. Describe with diagram the Anatomy of macula. Write in brief about macular function test.
More informationWork Sheet And Course Hand Out
Work Sheet And Course Hand Out This course provides the primary care health professional with a basic understanding of the eye, its function and the assessment of common sight- and non-sight threatening
More informationLong-Term Follow-up of Corneal and Sclero- Corneal Grafting in Severe Eye Perforations
Original Article Long-Term Follow-up of Corneal and Sclero- Corneal Grafting in Severe Eye Perforations Qasim Mansoor, Roa Rashad Qamar, S. Biswas, H.P. Adhikary Pak J Ophthalmol 2006, Vol. 22 No.2.................................................................................................
More informationClinical Policy Title: Therapeutic contact lenses
Clinical Policy Title: Therapeutic contact lenses Clinical Policy Number: 10.02.02 Effective Date: June 1, 2014 Initial Review Date: December 18, 2013 Most Recent Review Date: January 11, 2018 Next Review
More informationHorizon Scanning Centre March Ixekizumab for moderate to severe chronic plaque psoriasis SUMMARY NIHR HSC ID: 5209
Horizon Scanning Centre March 2015 Ixekizumab for moderate to severe chronic plaque psoriasis SUMMARY NIHR HSC ID: 5209 This briefing is based on information available at the time of research and a limited
More informationSCHEDULING STATUS Schedule 4 PROPRIETARY NAME AND DOSAGE FORM
Page 1 of 5 SCHEDULING STATUS Schedule 4 PROPRIETARY NAME AND DOSAGE FORM FML Liquifilm Sterile Eye Suspension COMPOSITION FML Liquifilm Sterile Eye Suspension contains: Fluorometholone 1,0 mg/ml Liquifilm
More informationClinical Policy: Refractive Surgery Reference Number: CP.MP. 391
Clinical Policy: Refractive Surgery Reference Number: CP.MP. 391 Effective Date: November 2007 Last Review Date: January 2016 Coding Implications Revision Log See Important Reminder at the end of this
More informationHorizon Scanning Technology Summary. Adalimumab (Humira) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Adalimumab (Humira) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationOPHTHALMOLOGY REFERRAL GUIDE FOR GPS
OPHTHALMOLOGY REFERRAL GUIDE FOR GPS A guidebook to support general practitioners in the management and referral of a range of common eye problems. Contents 3 Introduction 4 Ophthalmic Workup 6 Acute Visual
More informationPegvaliase for the treatment of hyperphenylalaninaemia in adults with phenylketonuria first line
May 2016 Horizon Scanning Research & Intelligence Centre Pegvaliase for the treatment of hyperphenylalaninaemia in adults with phenylketonuria first line LAY SUMMARY This briefing is based on information
More information